Interpreting Hydrogen and Methane Breath Tests in Patients Using GLP-1 Therapies

The following overview reflects common interpretation questions we encounter when reviewing breath test patterns in patients using GLP-1 therapy.

Many patients referred for breath testing are now commonly using GLP-1 receptor agonists. As the use of these medications has increased, testing interpretation questions have followed.

Many labs began noticing certain patterns shortly after GLP-1 therapies became widespread: patients with convincing gastrointestinal symptoms such as bloating, constipation, and gas were returning breath tests that looked delayed (rather than negative). The curves on the tests were different…but not random.

This observation has triggered a closer look at breath testing and what has changed physiologically, so clinicians can accurately interpret test findings.

Key Takeaways:

For clinicians evaluating patients using GLP-1 therapy:

• Breath testing remains clinically useful.
• Gas measurements are analytically accurate.
• Curve timing may shift due to slowed transit.
• Results should be interpreted together with the medication history.
• There are no consensus guidelines requiring routine discontinuation of GLP-1 therapy before testing.⁴

A Common Question: Can GLP-1 Patients Still Use Breath Testing?

The growing use and increased prevalence of GLP-1 treatments have led to the recurring practical concern among clinicians: Can breath testing results still be trusted for these patients?

The short answer is yes.

The longer, more nuanced answer is that the physiology surrounding the test changes, but the measurement itself does not. GLP-1 therapies often alter gastrointestinal motility. This changes the timing and the shape of the breath test curve patterns. But even though the required interpretation of the patterns changes, the validity of the test still stands. GLP-1 use doesn’t interfere with gas measurement technology. The body behaves a little differently, but the analyzer still measures the same thing.

Today’s hydrogen and methane analyzers measure exhaled gases directly. Changes in transit affect when fermentation occurs, not whether the gas itself is detectable.

It’s essential to separate motility effects from the measurement accuracy to preserve the significant diagnostic value of breath testing for SIBO, Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption evaluations. Without that distinction, delayed patterns can be mistaken for negative or unclear results.

The breath tests measure fermentation rather than speed. Clinicians often recognize this when reviewing serial samples—the curve looks shifted, rather than absent.

How GLP-1 Medications Affect the Gastrointestinal Tract

Breath analyzers measure gas concentration. GLP-1 medications influence transit. While those two variables are related, they are separate. GLP-1 receptor agonists are known to:

• Delay gastric emptying¹
• Slow small intestinal motility²
• Prolong overall gastrointestinal transit time³

The therapeutic effects of GLP-1 promote better glycemic control and appetite regulation. However, breath testing is partially dependent on a substrate’s movement through the digestive tract. Hydrogen and methane production reflect microbial fermentation over a period of time. So, when transit slows, fermentation still occurs, but it might happen later, more gradually, or across a wider interval.

Clinically, this means results often look like a delayed curve, rather than an absent one.

Understanding the Different Types of Breath Tests

Hydrogen and methane breath tests use different substrates depending on the clinical question, and these substrates can display different transit times.

Tests Used to Evaluate SIBO or Intestinal Methanogen Overgrowth

Glucose

Glucose tests are used to evaluate small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) patterns. Because glucose is absorbed in the proximal small intestine, fermentation usually occurs early if overgrowth is present.

With a slower transit time, that “early” rise in the testing curve may appear later than expected. We occasionally see this mistaken for a “normal” study (a negative result) when strict timing cutoffs are applied without consideration of the transit effects.

Lactulose

Lactulose testing is also used to evaluate SIBO and IMO patterns. As a substrate, lactulose is not absorbed quickly, but rather travels through the entire small intestine before reaching the colon. Interpretation, therefore, incorporates timing thresholds such as those described in the North American Consensus⁴.

In GLP-1 users, the curve may look less sharply divided into phases. This does not make it uninterpretable; it just requires some added context.

Tests Used to Evaluate Carbohydrate Malabsorption

• Lactose: Evaluates lactose digestion (lactose intolerance).
• Fructose: Evaluates fructose absorption capacity.

In these two carbohydrate malabsorption tests, fermentation occurs when the sugar substrates reach colonic bacteria due to incomplete absorption. The fermentation causes the production of measurable hydrogen and/or methane, which is interpreted by breath testing.

To summarize:

• Glucose and lactulose evaluate overgrowth patterns in SIBO/IMO.
• Lactose and fructose evaluate carbohydrate absorption.

When SIBO Testing Looks Different, What Is Usually Happening?

Because GLP-1 medications slow gastric emptying and intestinal transit, timing-based test interpretation patterns may shift.

• Delays in Glucose Breath Testing: Delayed gastric emptying may postpone glucose delivery to the proximal small intestine. Hydrogen or methane production may occur later than expected. When this is seen on a test, it represents delayed substrate exposure rather than the absence of overgrowth.
• Delays in Lactulose Breath Testing: Lactulose testing is especially sensitive to transit time. Slower transit may delay substrate progression to the small intestine, which then shifts the timing of the expected gas peaks. As a result, we often see broader or more prolonged curves.

When evaluating for SIBO and IMO, time-based criteria should be interpreted together with symptoms and medication history rather than used in isolation or as a solo diagnostic metric. It’s important to recognize that instead of a clean early-late separation, the rise of the results curve may unfold more gradually.

One common point of confusion occurs when a study appears “borderline normal” by strict timing criteria, yet symptoms and later samples suggest fermentation activity. In these situations, especially when GLP-1 use is part of a patient’s treatment regimen, transit effects often explain the discrepancy. It’s not that the growth is absent, but rather it’s delayed.

Do Carbohydrate Malabsorption Tests Become Unreliable for GLP-1 Users?

Carbohydrate malabsorption tests depend less on strict timing thresholds, but interpretation must still reflect the adjustment in transit dynamics.

Lactose Testing

If lactose is not digested by lactase in the small intestine, it reaches the colon and is fermented. Slower gastric emptying may delay the arrival of lactose arrival to the small intestine and the onset of fermentation. Therefore, results typically reflect prolonged gas production curves.

For diagnostic purposes, symptom correlation typically helps here more than just looking at timing. GLP-1 therapy does not cause lactose intolerance, but alters the curve shape of the results. Patients commonly report symptoms at their usual threshold, despite a later gas rise.

Fructose Testing

Fructose absorption depends on transporter capacity in the small intestine. Again, slowed transit can impact and modify exposure timing, delay the onset of fermentation, and produce sustained lower-level gas elevations.

Here, it’s important to note that the magnitude of the gas elevation remains clinically meaningful, even in cases where the timing shifts.

Methane, Motility, and GLP-1 Therapy

Methane production is associated with slower intestinal transit and constipation-predominant physiology⁵.

GLP-1 medications also slow intestinal transit. Because of this conjunction, sustained methane elevations may reflect both microbial activity and pharmacological motility effects. In other words, patients may not report classic constipation symptoms despite elevated methane levels.

Methane alone rarely tells the complete story. In practice, we find this is often the point where interpretation can diverge, and misinterpretation happens—not because the measurement of methane is unclear, but because motility physiology is being read as microbiology.

How Testing Patterns May Appear in Practice

Individual responses to breath tests differ from patient to patient. However, many of these variations in data reflect altered motility physiology rather than “false positive” testing.

Clinicians reviewing breath test results should incorporate medication history and GLP-1 use in the same way they consider antibiotics, laxatives, or motility disorders when evaluating breath test patterns. It’s important to look at the holistic picture.

In patients using GLP-1 therapy:

• Substrate arrival in the intestine may be delayed.
• Gas production may occur later.
• Testing curves may appear broader rather than sharply peaked.
• Methane levels may remain sustained at low-to-moderate levels.

These testing patterns reflect the altered motility physiology—the timing changes, but not a change in biology. These results don’t invalidate testing; they call for a wider perspective. Clinical interpretation should integrate medication use, health history, symptoms, and overall presentation.

Should Patients Stop GLP-1 Therapy Before Testing?

The question of stopping patients’ GLP-1 use before testing comes up frequently these days, but current guidance remains conservative.

• No formal consensus guidelines require discontinuation of GLP-1 therapy before hydrogen or methane breath testing.⁴
• Medication decisions should remain individualized.
• Patients should never stop prescribed medications without supervision.

Breath testing evaluates fermentation, absorption, and intestinal motility. GLP-1 therapy alters one of these variables—motility—but not the measurement itself.

In our experience, once clinicians recognize the predictable shift in curve timing, results remain clinically useful and consistent with patient presentation. The use of GLP-1 typically calls for an interpretative adjustment rather than a technical or physiological one.

This article is intended to support clinical interpretation and does not replace individual clinical judgment.

References

1. Nauck MA, et al. Effects of GLP-1 on gastric emptying in humans. Diabetologia. 1997.
2. Meier JJ, Nauck MA. GLP-1 effects on gastrointestinal motility. Best Pract Res Clin Endocrinol Metab. 2004.
3. Camilleri M, et al. Mechanisms of GLP-1 receptor agonists on GI motility. Gastroenterology. 2017.
4. Rezaie A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: North American Consensus. Am J Gastroenterol. 2017.
5. Pimentel M, et al. Methane production and slowed intestinal transit. Am J Gastroenterol. 2006.